These results indicate that a small fraction of the cellular PI4K activity is sufficient to maintain plasma membrane phosphoinositide pools and demonstrate the value of the pharmacological approach in revealing the pivotal role of PI4KIIIα enzyme in maintaining plasma membrane phosphoinositides.
INTRODUCTION
Activation of cell surface receptors by a variety of stimuli initiates a cascade of molecular events ultimately eliciting a response characteristic of the target cell. One of the most studied and best-characterized signal transduction pathways is initiated by the phospholipase C (PLC)-mediated breakdown of PtdIns(4,5)P 2 to generate the Ca 2+ -mobilizing messenger, InsP 3 and the PKC activator, DAG (Berridge and Irvine, 1984) . It has long been recognized that the sustained production of these messengers requires continuous phosphorylation of PtdIns to PtdIns4P and PtdIns(4,5)P 2 by PI 4-kinase and PIP 5-kinase enzymes, due to the limited amount of PtdIns(4,5)P 2 present in the plasma membrane (Creba et al., 1983) . Several isoforms within the PI 4-kinase and PIP 5-kinase families have been described (Doughman et al., 2003; Balla and Balla, 2006) , and a recent study identified a splice variant of PIP 5-kinase γ as the enzyme responsible for PtdIns4P to PtdIns(4,5)P 2 conversion in agonist-induced Ca 2+ signaling (Wang et al., 2004) . In contrast, the PI 4-kinase that generates PtdIns4P for this process so far has eluded identification.
Four PI 4-kinase enzymes have been identified in mammalian cells that belong to either the type II or type III families . Type II PI 4-kinase enzymes (α-and β-forms) are small, 56 kDa proteins that are abundant in almost all cellular membranes and are enriched in plasma membrane preparations. They are kept in the membrane by palmitoylation, and recent studies suggest that these enzymes have a role in post-TGN trafficking (Wang et al., 2003; Wang et al., 2007) and the endocytic processing of the EGF receptors (Minogue et al., 2006) . Type III PI 4-kinases (α-and β-forms), on the other hand, are soluble enzymes structurally related to PI 3-kinases and can be inhibited by higher concentrations of PI 3-kinase inhibitors, such as wortmannin (Wm). We have reported over 10 years ago that production of the agonist-sensitive phosphoinositide pools required the activity of Wm-sensitive type III PI 4-kinase enzymes (Nakanishi et al., 1995) . However, it is still not known which of the type III enzymes participates in the formation of the agonist-regulated PtdIns4P pools.
In the present study we used both pharmacological and genetic approaches to interfere with the activity of all of the PI 4-kinase enzymes and monitored phosphoinositide changes both by conventional metabolic labeling of inositol lipids andphosphates and by employing GFP-tagged PH domains specifically recognizing PtdIns4P
and PtdIns(4,5)P 2 . These results show that the PH domain of the yeast OSH2 protein is a valuable tool to monitor plasma membrane PtdIns4P pools and that PI 4-kinase IIIα is required for sustained InsP 3 production and Ca 2+ signaling. Although this conclusion was supported by siRNA-mediated gene silencing of the individual PI4K enzymes, the present studies also highlight the difficulties in obtaining conclusive data with siRNA on enzymes whose functions are near essential and emphasize the value of inhibitors to dissect the roles of these proteins in cellular signaling.
MATERIALS AND METHODS

Materials:
Wortmannin and ionomycin were purchased from Calbiochem. Phenylarsine oxyde (PAO), β-mercaptoethanol, dithiothreitol and poly-Lysine were obtained from Sigma. Fura-2/AM and Pluronic acid were from Molecular Probes/Invitrogen. PIK93 was synthesized as previously described (Knight et al., 2006) . Myo-[ 3 H]inositol (60 Ci/mmol) was purchased from Amersham-Pharmacia and ortho-32 P-phosphate (9000 was purchased from UBI, the polyclonal antibody against PI4KIIα was a kind gift from Dr. Pietro De Camilli and the anti PI4KIIIα antibody was raised in New Zealand rabbits as previously described (Balla et al., 2005) .
DNA constructs and transfections:
The OSH2-2x-GFP construct was generated by amplifying the PH domain sequence of OSH2 (residues: 256-424) from S. cerevisiae cDNA (ATCC) using two primer pairs to obtain fragments flanked by XhoI/EcoRI and EcoRI/KpnI sites. These fragments were then cloned in tandem between the XhoI/KpnI sites of the pEGFP-C1 plasmid (Clontech) with a linker (VNSKL) in between them following the design of Roy and Levine (Roy and Levine, 2004) . The single PH domain version of the PH domain has also been created as well as the cyan and yellow fluorescent versions of the tandem construct. The PLCδ 1 PH-GFP construct (Várnai and Balla, 1998) and its color variants have been previously described (Varnai et al., 2002) .
The OSH1-PH-GFP was kindly provided by Dr. Mark Lemmon (Yu et al., 2004) , and the type IV phosphoinositide 5-phosphatase was a kind gift of Dr. Philip Majerus (Kisseleva et al., 2000) . The constructs used for the rapamycin-inducible translocation of the type-IV phosphoinositide 5-phosphatase have been described recently (Varnai et al., 2006) .
The HEK-293AT1 cells used for these studies have been stably transfected with the HA-AT1a and FLAG-AT1a angiotensin receptors in two rounds of selection using G418 and Zeocine for the two constructs, respectively. These cells were kindly provided by Drs. Alberto Jesus Olivares-Reyes and Kevin J. Catt. Cells were cultured in DMEM with Pen/Strep and 10% FBS and have been subjected to a G418/Zeo selection from time to time but not during cultures for the experiments.
For RNAi-mediated knock-down the cells were cultured either in 10 cm dishes (for suspension Ca 2+ measurements), 12 well plates (for metabolic labeling studies) or 25 mm glass coverslips treated with poly-Lysine (for single cell Ca 2+ or confocal studies).
The duplexes used for treatment have been previously described (Balla et al., 2005) .
Cells were treated with 100 nM siRNA twice in consecutive days and were analyzed on the 4th day after the first treatment.
Analysis of single cells for FRET, cytoplasmic Ca 2+ measurements and confocal microscopy: HEK-293AT1 cells were cultured on glass coverslips (3x10 5 cells/35mm dish) pretreated with poly-Lysine and transfected with the various constructs (0.5-2µg DNA /dish) using Lipofectamine 2000 for 24 h as described elsewhere (Varnai et al., 2005 (Nakanishi et al., 1995) . The cell pellet was also processed to extract the phosphoinositides by an acidic chloroform/methanol extraction followed by TLC analysis essentially as described previously (Nakanishi et al., 1995) . 32 P-labeled cells were not washed after the labeling period, but were treated in the same medium with inhibitors for 10 min followed by AngII (10 -7 M) stimulation.
Reactions were terminated by PCA and lipids were extracted and separated as with the inositol-labeled cells. between the α and β forms of these PI4Ks based on their Wm sensitivities (Balla et al., 1997; Knight et al., 2006) . Therefore, we took advantage of the recent characterization of isoform-specific PI 3-kinase inhibitors that revealed one of the inhibitors, PIK93, as being significantly more potent against PI4KIIIβ than PI4KIIIα ( Knight et al., 2006) .
RESULTS
Pharmacological
This inhibitor inhibits PI 3-kinases and clearly discriminates between the two PI 4-kinase enzymes as assessed by an in vitro PI kinase assay on the purified mammalian proteins (Knight et al., 2006) . Unfortunately, none of the tested inhibitors showed the opposite selectivity, i.e. inhibition of PI4KIIIα more potently than the PI4KIIIβ enzyme.
Phenylarsine oxide (PAO) an SH reactive agent has been shown earlier to inhibit PI4Ks (Wiedemann et al., 1996) . PAO was found to inhibit type III PI 4-kinases whereas it is relatively ineffective against the type II enzymes based on in vitro kinase assays of the purified proteins Barylko et al., 2002) . Among the type III enzymes, PI4KIIIα is significantly more sensitive to PAO than the type IIIβ form . This difference was also exploited to discriminate between the two enzymes in their involvement to generate the hormone-sensitive PtdIns4P pools. It is important to emphasize that PAO is a SH-reactive agent that probably has many targets in a cell.
However, in the present study, the effects of PAO have only been tested on parameters that immediately reflect PI 4-kinase functions (see below) and therefore in this narrow context the effects of PAO on the purified PI 4-kinases and PtdIns4P formation in the intact cell can be correlated with somewhat higher confidence. These effects of Wm were not observed at lower concentrations (below 300 nM) that already inhibit PI 3-kinases (data not shown), and were clearly caused by the limited supply of PtdIns4P and PtdIns(4,5)P 2 consistent with the inhibition of a PI4K that helps replenishing these pools during a sustained PLC activation. This is demonstrated in Fig. 2, where the 32 P-phosphate-labeled PtdIns4P and PtdIns(4,5)P 2 were analyzed in AngII stimulated cells. Without the inhibitors, AngII stimulation evokes a robust PLC activation resulting in the rapid depletion of PtdIns(4,5)P 2 that slowly returns toward prestimulatory levels. A similar change is observed in PtdIns4P levels due to the conversion of this lipid to PtdIns(4,5)P 2 by the PIP 5-kinases and its relatively slower synthesis by the PI4Ks. Pretreatment of the cells with 10 µM Wm greatly reduced the 32 Plabeled PtdIns4P and, hence, the AngII-induced changes observed in HEK-293-AT1 cells (Fig. 1A ), but only slightly reduced basal PtdIns(4,5)P 2 levels. However, this treatment significantly enhanced the AngII-induced decrease in PtdIns(4,5)P 2 and strongly inhibited its resynthesis (Fig. 2B ).
These effects of Wm were not reproduced by 250 nM PIK93, which inhibits PI4KIIIβ (and the PI 3-kinases) but not PI4KIIIα (Knight et al., 2006) , and which was found as effective as 10 µM Wm in inhibiting the ER to Golgi transport of ceramide, a process linked to PI4KIIIβ function (Toth et al., 2006) . PIK93 failed to affect either the InsP 3 and Ca 2+ changes or those of the 32 P-labeled phosphoinositides during AngIIstimulation (Figs 1 and 2). The effect of PAO was tested at a concentration of 10 µM (applied in the presence of 1 mM β-mercaptoethanol to reduce its side effects). Although at this concentration PAO only partially inhibits PI4KIIIα (~80 %), it was chosen because it does not yet inhibit PI4KIIIβ . As shown in Fig domains that recognize PtdIns4P and PtdIns(4,5)P 2 . PtdIns(4,5)P 2 changes were followed in single cells by either confocal microscopy or by FRET analysis using YFP and CFPtagged versions of the PLCδ PH domain (van Der Wal et al., 2001) .
Cells were stimulated with AngII for the indicated times followed by the addition of high concentration (10 µM) of Ionomycin to activate PLC and to eliminate PLCδ 1 PH-GFP localization and FRET (Várnai and Balla, 1998; Balla et al., 2005) . Subsequent addition of BAPTA (or EGTA) was used to reverse the Ca 2+ change and allow the PtdIns(4,5)P 2 pools to recover. As shown in Fig When the effects of Wm were tested in similar experiments, we encountered several technical difficulties. First, the inhibitory effects of Wm showed a strong lightinduced reversal in single-cell experiments. At shorter excitation wavelengths these effects were stronger, making it essentially impossible to monitor the effect of Wm on single cell Ca 2+ responses with Fura-2. (The photon flux density is significantly lower during Ca 2+ measurements in cell-suspension, therefore those measurements are less sensitive to this effect). In addition, a significant drift was observed in the FRET baseline during the 10 min Wm preincubation period (without illumination). Although this was partially eliminated rapidly after 2-3 light scans, it was difficult to assess the basal FRET values after Wm treatment. Therefore the data on the effects of Wm (still partially inhibitory) were not included in this analysis.
Evaluation of the OSH2 PH domain as a probe of plasma membrane PtdIns4P levels.
None of the type III PI4K enzymes can be detected by immunofluorescence at the plasma membrane, yet PtdIns4P has to be present in the plasma membrane to be converted to PtdIns(4,5)P 2 . To obtain information on the activity rather than the steady-state cellular distribution of the PI4K enzymes, it was highly desirable to use reporter probes that monitor PtdIns4P production in single cells. PH domain-GFP chimeras with high in vitro PtdIns4P binding specificities, such as the FAPP1 or OSBP PH domains have been used for this purpose, but these probes mostly report on PtdIns4P formed in the Golgi as they also require Arf1-GTP for their Golgi recruitment (Levine and Munro, 2002; Godi et al., 2004; Balla et al., 2005) . Although both of these PH domains can detect PtdIns4P formation in the plasma membrane under special circumstances (Balla et al., 2005) , they are not optimal for monitoring PtdIns4P in the plasma membrane. It has recently been shown by two independent studies that the PH domain of the yeast oxysterol binding protein homologue, OSH2 recognizes PtdIns4P in the plasma membrane, in spite of its limited specificity to bind PtdIns4P in vitro (Roy and Levine, 2004; Yu et al., 2004) . Therefore, first, we wanted to determine whether the OSH2 PH domain could, in fact, be used to follow PtdIns4P changes in the plasma membrane of mammalian cells.
Expression of the single PH domain of OSH2 fused to GFP showed clear plasma membrane localization and a strong nuclear staining as previously described (Roy and Levine, 2004; Yu et al., 2004) . Using two PH domains in tandem fused to GFP (GFP-OSH2-PH2x) greatly reduced the nuclear localization of the construct and clearly labeled the plasma membrane (Fig. 4A) . Importantly, unlike in yeast cells, neither the tandem nor the single OSH2 PH domain decorated the Golgi membrane in COS-7 or HEK293 cells (Fig. 4A ). In contrast, the yeast OSH1 PH domain labeled both the plasma membrane (at high expression levels) and the Golgi (Fig. 4A ). Since the OSH2 PH domain has limited in vitro specificity to PtdIns4P (Yu et al., 2004) , we were concerned that it may be recruited to the plasma membrane by PtdIns(4,5)P 2 . The specificity question was examined with our recently developed method of acute depletion of PtdIns(4,5)P 2 in the plasma membrane. This approach is based on a drug induced plasma membrane recruitment of a truncated type-IV phosphoinositide 5-phosphatase (5-ptase) that was rendered cytoplasmic by mutations in its localization sequences (Varnai et al., 2006) . Recruitment of this cytoplasmic 5-ptase to the plasma membrane rapidly eliminated PtdIns(4,5)P 2 as monitored by PLCδ 1 PH-GFP localization (Fig. 4B ), without elimination of the GFP-OSH2-PH2x localization (Fig. 4C ). This question was further analyzed in TIRF experiments where the release of the PH domain from the membrane can be better quantified. These experiments showed no effect of the phosphatase recruitment on GFP-OSH2-PH2x localization while eliminating PLCδ1PH-GFP localization in COS-7 cells (Korzeniowski and Balla, unpublished observations).
In a separate set of studies performed in COS-7 cells, the wild-type 5-ptase enzyme was expressed together with the mRFP-fused PLCδ1PH domain and the GFP-OSH2-PH2x construct. This triple transfection yielded many cells in which the plasma membrane localization of the PLCδ1PH-mRFP construct was eliminated indicating the depletion of PtdIns(4,5)P 2. , yet the localization of the OSH2-PH2x was still preserved (Fig. 5A ). These studies also confirmed that the OSH2-PH2x was not recruited to the membrane by PtdIns(4,5)P 2 . When such cells were treated with 10 µM Wm, the localization of OSH2-PH2x was rapidly eliminated (Fig. 5A ). Lower concentrations of Wm specific for PI 3-kinases had no such effect (not shown), indicating that the plasma membrane pool of PtdIns4P monitored by OSH2-PH2x requires the activity of type III PI 4-kinases. Notably, Wm exerted a much slower effect on OSH2-PH2x localization in cells not expressing the 5-phosphatase ( Fig. 5B and see below) indicating that the dephosphorylation of PtdIns(4,5)P 2 probably contributes to maintaining PtdIns4P levels in the membrane for a period of time when PI4K is inhibited.
The PH domain of OSH2 follows agonist-induced changes of PtdIns4P levels.
Next we determined whether GFP-OSH2-PH2x localization is affected by agonistinduced PLC activation. HEK-293-AT1 cells were co-transfected with the PLCδ1PH-mRFP and GFP-OSH2-PH2x for simultaneous monitoring of PtdIns(4,5)P 2 and PtdIns4P.
As shown in Fig. 6 , both constructs showed a rapid and transient translocation from the plasma membrane to the cytosol after AngII addition, but with notable kinetic differences. The translocation of the GFP-OSH2-PH2x occurred with a clearly measurable (about 5 seconds) delay compared to that of PLCδ1PH-mRFP. The kinetics of changes in GFP-OSH2-PH2x localization after AngII addition was indistinguishable regardless whether cells were preincubated with 10 mM Li + or not (not shown). Since
Ins(1,4)P 2 levels accumulate to very high levels and remain elevated in Li + -treated cells (e.g. (Balla et al., 1988) due to the inhibition of the phosphatase that dephosphorylates Ins(1,4)P 2 (Majerus et al., 1999) , these findings suggest that the AngII-induced translocation of the GFP-OSH2-PH2x protein from the membrane is caused by the changes in membrane PtdIns4P levels rather than increases in Ins(1,4)P 2 levels in the cytosol. The slight delay in the response of GFP-OSH2-PH2x compared to that of PLCδ1PH-mRFP may reflect the slower (probably Ca 2+ dependent) activation of the PLC isoform that hydrolyses PtdIns4P, or a slight delay in the conversion of PtdIns4P to PtdIns(4,5)P 2 , but the contribution of the rapid Ins(1,4,5)P 3 increase to PLCδ1PH-mRFP translocation can also be responsible for its faster kinetics. Nevertheless, these data together were consistent with the conclusion that the GFP-OSH2-PH2x reporter can monitor plasma membrane PtdIns4P changes during agonist activation.
Pharmacological manipulations of the membrane localization of OSH2-2x-PH.
In response to the PI 4-kinase inhibitors, the GFP-OSH2-PH2x domain showed changes in good agreement with the 32 P-phosphate and myo-[ (Fig. 7A ). Subsequent addition of AngII rapidly eliminated the remaining localization and no re-localization of the probe was observed throughout the 10 min stimulation (Fig. 8A) . It is important to note that the effects of Wm became almost undetectable when prolonged rapid sampling of the confocal pictures was used to follow localization of the PH domains. This was again attributed to the photo-lability of Wm inhibition discussed above and also observed in (Warashina, 1999) . 10 µM PAO (with 1 mM β-mercaptoethanol) had a similar inhibitory effect on the basal localization, although this treatment did not evoke the same decrease as Wm did before AngII addition (Fig.   7B ). The effect of PAO was completely reversed by simultaneous addition of 1 mM DTT (Fig. 7B) . PAO also completely prevented the re-localization of the GFP-OSH2-PH2x during AngII stimulation (Fig. 8B) . In contrast, PIK93 (250 nM) had no effect on either the basal localization of the GFP-OSH2-PH2x probe (Fig. 7C ) nor did it affect the response to AngII stimulation (Fig. 8A ).
The effects of RNAi-mediated knock-down on phosphoinositides and Ca 2+ signaling.
The results of the pharmacological analysis pointed to PI4KIIIα as the enzyme important in the maintenance of the agonist-sensitive phsophoinositide pools of the plasma membrane. We wanted to confirm these data with RNAi-mediated gene silencing. All down-regulated groups (Fig. 9B ). To normalize for this difference, in each experiments the ratio of PtdIns4P and PtdIns(4,5)P 2 to the PtdIns/PtdA spots from unstimulated cells were calculated and compared between the control siRNA or PI4K siRNA treated groups.
After such corrections, the labeling of both PtdIns4P and PtdIns(4,5)P 2 showed a ~25% decrease upon depletion of either of PI4KIIα, PI4KIIIα or PI4KIIIβ. This difference was statistically significant (p<0.05) for all enzyme knock-downs in PtdIns4P but only for PI4KIIα in PtdIns(4,5)P 2 (Fig. 9C ). To assess PtdIns4P and PtdIns(4,5)P 2 synthesis during stimulation, the level of these lipids were measured after 10 min of AngII exposure, since by this time impaired resynthesis of these lipids was expected to be detectable (see Fig.2 for full kinetics). In these experiments we also included treatment with 250 nM PIK93 before AngII treatment for each group to determine whether compensatory changes in PI4KIIIβ (although not apparent by Western analysis) could mask the effects of PI4KIIα or PI4KIIIα knock-down. Since there was absolutely no difference between the PIK93-AngII treated group and those only treated with AngII alone (not shown) these measurements have been combined for statistical analysis.
As shown in Fig. 9C , by 10 min of AngII treatment, PtdIns(4,5)P 2 and PtdIns4P levels returned to about 60-70% of their prestimulatory values (see also in Fig. 2 ) in control cells 1 . However, in cells depleted in PI4KIIIα, this value was significantly (p<0.05) lower (~50%) for both lipids, the difference being more pronounced in PtdIns(4,5)P 2 which could be measured with better accuracy. These differences were relatively minor and required a fine balance between siRNA treatment that still preserved enough cells for analysis yet showed sufficient knock-down to capture even these small changes.
In cells labeled with myo-[
3 H]inositol the picture was further complicated as we observed an increased labeling of PtdIns4P and PtdIns(4,5)P 2 (and the inositol phosphates) in cells in which PI4KIIIα was depleted. This paradoxical change was attributed to a significant decrease in the free inositol level of PI4KIIIα knock-down cells and hence an increased specific activity of the labeled inositol pool (not shown). The reason for the consistent decrease in the level of inositol in cells depleted in PI4KIIIα is not known and is currently under further investigation.
DISCUSSION
In the present studies we asked the question of which of the PI4K enzymes is important for the generation of the plasma membrane pool of PtdIns4P, the precursor of PtdIns(4,5)P 2 during PLC activation in agonist-stimulated cells. This question has not been thoroughly addressed before for lack of appropriate tools to investigate it properly.
In a previous study we showed that Wm-sensitive type III PI4Ks are required for the maintenance of agonist-sensitive phosphoinositide pools and hence Ins(1,4,5)P 3 and calcium signaling (Nakanishi et al., 1995) . These studies have been confirmed in other laboratories using different cell lines and different Ca 2+ -mobilizing receptors and agonists (Willars et al., 1998) , but the identity of the enzyme(s) responsible for supplying These studies using PH domains of PLCδ 1 and OSH2-PH2x to monitor PtdIns(4,5)P 2 and PtdIns4P, respectively, confirmed the conclusions of the labeling and Ca 2+ experiments that PI4KIIIα is the enzyme necessary for the maintenance of the plasma membrane pool of these lipids. The exact mechanism how this is achieved by the enzyme that is primarily ER/Golgi localized remains to be answered, but its is quite possible that a small fraction of the enzyme is in fact found at the plasma membrane regulated by a unique mechanism, while the larger fraction of the protein has additional functions in the ER/Golgi compartments. It is interesting to note that in Saccharomyces cerevisiae the Stt4p PI4K, a homologoue of PI4KIIIα, was reported to generate the plasma membrane PtdIns4P pool, but unlike in mammalian cells, the yeast enzyme is primarily found in the plasma membrane or a tightly associated compartment (Audhya and Emr, 2002) . Paradoxically, there are well-documented ER and vacuolar functions of Stt4p in yeast, yet the protein has not been detected in those locations (Trotter et al., 1998; Audhya et al., 2000) .
RNAi-mediated depletion of the individual PI4Ks has produced only small effects on 32 P-labeled PtdIns4P and PtdIns(4,5)P 2 but confirming the identity of the PI4KIIIα enzyme as one responsible for PtdIns4P and PtdIns(4,5)P 2 production at the plasma In recent studies we were able to show the role of PI4Ks in other aspects of cellular PtdIns4P production where the knock-down data gave as clear results as the pharmacological approach. These included the recruitment of the FAPP1PH domain to the Golgi being mediated by both the PI4KIIIβ and PI4KIIα enzymes (Balla et al., 2005) , and the role of PI4KIIIβ in the ER to Golgi transport of ceramide (Toth et al., 2006) . In fact, in the former study we found that PI4KIIIα knock-down was able to decrease the plasma membrane recruitment of the FAPP1PH domain during recovery from a large Ca 2+ -mediated PLC activation (Balla et al., 2005) . These studies collectively suggest that PI4Ks probably have multiple functions within the cells that are affected at different level of enzyme depletion.
Lastly, these studies utilizing the FAPP1PH, OSBP-PH and OSH2-PH domains highlight the values as well as the limitations of PH domain reporters. These studies clearly demonstrate that specific pools of PtdIns4P are detected by the individual probes and one reporter may not detect PtdIns4P in all locations within the cells. The FAPP1
and OSBP PH domains detect primarily the Golgi pool, although under special circumstances such as during recovery from massive Ca 2+ induced PLC activation they can also detect PtdIns4P in the plasma membrane (Balla et al., 2005) . In contrast, the OSH2-2x-PH-GFP reporter detects PtdIns4P in the plasma membrane but not in the Golgi compartment in mammalian cells. Only the yeast OSH1-PH decorates both the Golgi and the plasma membrane. Importantly, the plasma membrane localization of all of the PtdIns4P reporters depends on the activity of Wm-sensitive, type III PI4Ks, and based on the current studies specifically of the PI4KIIIα enzyme.
In summary, the present results establish PI4KIIIα as an important component of the generation of the plasma membrane pool of phosphoinositides. This conclusion is based on pharmacological studies and confirmed by RNAi-mediated gene silencing although the latter could not decrease the enzyme levels sufficiently to appreciably impair Ca 2+ signaling. These studies also establish the OSH2-PH2x domain as a useful reporter to follow PtdIns4P changes in the plasma membrane. Further studies are in progress to identify the mechanism by which the apparently ER/Golgi localized PI4KIIIα can affect the supply of plasma membrane PtdIns4P. 
